Aliskiren versus ramipril in hypertension (Q37736951)

22 August 2017

1 reference

title

Aliskiren versus ramipril in hypertension (English)

1 reference

22 August 2017

main subject

arterial hypertension

0 references

7

Gianpaolo Reboldi

1 reference

22 August 2017

Paolo Verdecchia

1

1 reference

22 August 2017

Fabio Angeli

2

1 reference

22 August 2017

Giovanni Mazzotta

3

1 reference

22 August 2017

Paola Martire

4

1 reference

22 August 2017

Marta Garofoli

5

1 reference

22 August 2017

Giorgio Gentile

6

1 reference

22 August 2017

publication date

23 April 2010

1 reference

Therapeutic advances in cardiovascular disease

22 August 2017

published in

1 reference

22 August 2017

volume

4

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

193-200

1 reference

Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Prediction of myocardial infarction by N-terminal-pro-B-type natriuretic peptide, C-reactive protein, and renin in subjects with cerebrovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Developing optimal search strategies for detecting clinically sound studies in MEDLINE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Clinical pharmacokinetics of ramipril

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Managing cardiovascular and renal risk: the potential of direct renin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

21 January 2018

Oral renin inhibitors

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944710369682

21 January 2018

Identifiers

DOI

10.1177/1753944710369682

1 reference

22 August 2017

1 reference